 | • レポートコード：MRC2102QY9834 • 出版社/出版日： / 2021年1月 • レポート形態：英文、PDF、146ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥592,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥888,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,184,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYリサーチ社の本調査レポートでは、世界の非チロシンキナーゼ阻害剤市場について種類別（mTOR阻害剤、RAF/MEK阻害剤、CDK阻害剤）、用途別（肝臓がん、呼吸器がん、脳腫瘍、その他）、地域別（米国、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・非チロシンキナーゼ阻害剤市場の概要 ・世界の主要地域別非チロシンキナーゼ阻害剤市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の非チロシンキナーゼ阻害剤市場規模2015-2026：種類別（mTOR阻害剤、RAF/MEK阻害剤、CDK阻害剤） ・世界の非チロシンキナーゼ阻害剤市場規模2015-2026：用途別（肝臓がん、呼吸器がん、脳腫瘍、その他） ・非チロシンキナーゼ阻害剤の米国市場規模2015-2020 ・非チロシンキナーゼ阻害剤のヨーロッパ市場規模2015-2020 ・非チロシンキナーゼ阻害剤の中国市場規模2015-2020 ・非チロシンキナーゼ阻害剤の日本市場規模2015-2020 ・非チロシンキナーゼ阻害剤の東南アジア市場規模2015-2020 ・非チロシンキナーゼ阻害剤のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・非チロシンキナーゼ阻害剤の製造コスト分析 ・販売チャネル、流通業者、顧客 ・非チロシンキナーゼ阻害剤の市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global Non-Tyrosine Kinase Inhibitors Market
The global Non-Tyrosine Kinase Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Non-Tyrosine Kinase Inhibitors Scope and Market Size
The global Non-Tyrosine Kinase Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non-Tyrosine Kinase Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Non-Tyrosine Kinase Inhibitors market is segmented into
mTOR Inhibitors
RAF/MEK Inhibitors
CDK Inhibitors
Segment by Application, the Non-Tyrosine Kinase Inhibitors market is segmented into
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
The Non-Tyrosine Kinase Inhibitors market is analysed and market size information is provided by regions (countries). Segment by Application, the Non-Tyrosine Kinase Inhibitors market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Non-Tyrosine Kinase Inhibitors Market Share Analysis
Non-Tyrosine Kinase Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Non-Tyrosine Kinase Inhibitors business, the date to enter into the Non-Tyrosine Kinase Inhibitors market, Non-Tyrosine Kinase Inhibitors product introduction, recent developments, etc.
The major vendors covered:
Roche
Eli Lilly
Novartis
Array BioPharma
Nerviano Medical Sciences
Pfizer
Merck KGaA
Astex Pharmaceuticals
Cyclacel Pharmaceuticals
Daiichi Sankyo
Onconova Therapeutics
AstraZeneca
GlaxoSmithKline (GSK)
Carna Biosciences
Celgene Corporation
Eternity Bioscience
Jasco Pharmaceuticals
1 Non-Tyrosine Kinase Inhibitors Market Overview
1.1 Non-Tyrosine Kinase Inhibitors Product Scope
1.2 Non-Tyrosine Kinase Inhibitors Segment by Type
1.2.1 Global Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2026)
1.2.2 mTOR Inhibitors
1.2.3 RAF/MEK Inhibitors
1.2.4 CDK Inhibitors
1.3 Non-Tyrosine Kinase Inhibitors Segment by Application
1.3.1 Global Non-Tyrosine Kinase Inhibitors Sales Comparison by Application (2020-2026)
1.3.2 Liver Cancer
1.3.3 Respiratory Cancer
1.3.4 Brain Cancer
1.3.5 Others
1.4 Non-Tyrosine Kinase Inhibitors Market Estimates and Forecasts (2015-2026)
1.4.1 Global Non-Tyrosine Kinase Inhibitors Sales Growth Rate (2015-2026)
1.4.2 Global Non-Tyrosine Kinase Inhibitors Revenue and Growth Rate (2015-2026)
1.4.3 Global Non-Tyrosine Kinase Inhibitors Price Trends (2015-2026)
2 Non-Tyrosine Kinase Inhibitors Estimate and Forecast by Region
2.1 Global Non-Tyrosine Kinase Inhibitors Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Non-Tyrosine Kinase Inhibitors Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Region (2015-2020)
2.2.2 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Region (2015-2020)
2.3 Global Non-Tyrosine Kinase Inhibitors Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Non-Tyrosine Kinase Inhibitors Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Non-Tyrosine Kinase Inhibitors Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Non-Tyrosine Kinase Inhibitors Estimates and Projections (2015-2026)
2.4.2 Europe Non-Tyrosine Kinase Inhibitors Estimates and Projections (2015-2026)
2.4.3 China Non-Tyrosine Kinase Inhibitors Estimates and Projections (2015-2026)
2.4.4 Japan Non-Tyrosine Kinase Inhibitors Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Non-Tyrosine Kinase Inhibitors Estimates and Projections (2015-2026)
2.4.6 India Non-Tyrosine Kinase Inhibitors Estimates and Projections (2015-2026)
3 Global Non-Tyrosine Kinase Inhibitors Competition Landscape by Players
3.1 Global Top Non-Tyrosine Kinase Inhibitors Players by Sales (2015-2020)
3.2 Global Top Non-Tyrosine Kinase Inhibitors Players by Revenue (2015-2020)
3.3 Global Non-Tyrosine Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Tyrosine Kinase Inhibitors as of 2019)
3.4 Global Non-Tyrosine Kinase Inhibitors Average Price by Company (2015-2020)
3.5 Manufacturers Non-Tyrosine Kinase Inhibitors Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Non-Tyrosine Kinase Inhibitors Players (Opinion Leaders)
4 Global Non-Tyrosine Kinase Inhibitors Market Size by Type
4.1 Global Non-Tyrosine Kinase Inhibitors Historic Market Review by Type (2015-2020)
4.1.1 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
4.1.2 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Type (2015-2020)
4.1.3 Global Non-Tyrosine Kinase Inhibitors Price by Type (2015-2020)
4.2 Global Non-Tyrosine Kinase Inhibitors Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Non-Tyrosine Kinase Inhibitors Sales Forecast by Type (2021-2026)
4.2.2 Global Non-Tyrosine Kinase Inhibitors Revenue Forecast by Type (2021-2026)
4.2.3 Global Non-Tyrosine Kinase Inhibitors Price Forecast by Type (2021-2026)
5 Global Non-Tyrosine Kinase Inhibitors Market Size by Application
5.1 Global Non-Tyrosine Kinase Inhibitors Historic Market Review by Application (2015-2020)
5.1.1 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
5.1.2 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Application (2015-2020)
5.1.3 Global Non-Tyrosine Kinase Inhibitors Price by Application (2015-2020)
5.2 Global Non-Tyrosine Kinase Inhibitors Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Non-Tyrosine Kinase Inhibitors Sales Forecast by Application (2021-2026)
5.2.2 Global Non-Tyrosine Kinase Inhibitors Revenue Forecast by Application (2021-2026)
5.2.3 Global Non-Tyrosine Kinase Inhibitors Price Forecast by Application (2021-2026)
6 United States Non-Tyrosine Kinase Inhibitors Market Facts & Figures
6.1 United States Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2015-2020)
6.2 United States Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
6.3 United States Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
7 Europe Non-Tyrosine Kinase Inhibitors Market Facts & Figures
7.1 Europe Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2015-2020)
7.2 Europe Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
7.3 Europe Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
8 China Non-Tyrosine Kinase Inhibitors Market Facts & Figures
8.1 China Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2015-2020)
8.2 China Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
8.3 China Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
9 Japan Non-Tyrosine Kinase Inhibitors Market Facts & Figures
9.1 Japan Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (3015-3030)
9.2 Japan Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
9.3 Japan Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
10 Southeast Asia Non-Tyrosine Kinase Inhibitors Market Facts & Figures
10.1 Southeast Asia Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
11 India Non-Tyrosine Kinase Inhibitors Market Facts & Figures
11.1 India Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2015-2020)
11.2 India Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
11.3 India Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Non-Tyrosine Kinase Inhibitors Business
12.1 Roche
12.1.1 Roche Corporation Information
12.1.2 Roche Business Overview
12.1.3 Roche Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Roche Non-Tyrosine Kinase Inhibitors Products Offered
12.1.5 Roche Recent Development
12.2 Eli Lilly
12.2.1 Eli Lilly Corporation Information
12.2.2 Eli Lilly Business Overview
12.2.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Eli Lilly Non-Tyrosine Kinase Inhibitors Products Offered
12.2.5 Eli Lilly Recent Development
12.3 Novartis
12.3.1 Novartis Corporation Information
12.3.2 Novartis Business Overview
12.3.3 Novartis Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Novartis Non-Tyrosine Kinase Inhibitors Products Offered
12.3.5 Novartis Recent Development
12.4 Array BioPharma
12.4.1 Array BioPharma Corporation Information
12.4.2 Array BioPharma Business Overview
12.4.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Array BioPharma Non-Tyrosine Kinase Inhibitors Products Offered
12.4.5 Array BioPharma Recent Development
12.5 Nerviano Medical Sciences
12.5.1 Nerviano Medical Sciences Corporation Information
12.5.2 Nerviano Medical Sciences Business Overview
12.5.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Products Offered
12.5.5 Nerviano Medical Sciences Recent Development
12.6 Pfizer
12.6.1 Pfizer Corporation Information
12.6.2 Pfizer Business Overview
12.6.3 Pfizer Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Pfizer Non-Tyrosine Kinase Inhibitors Products Offered
12.6.5 Pfizer Recent Development
12.7 Merck KGaA
12.7.1 Merck KGaA Corporation Information
12.7.2 Merck KGaA Business Overview
12.7.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Merck KGaA Non-Tyrosine Kinase Inhibitors Products Offered
12.7.5 Merck KGaA Recent Development
12.8 Astex Pharmaceuticals
12.8.1 Astex Pharmaceuticals Corporation Information
12.8.2 Astex Pharmaceuticals Business Overview
12.8.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Products Offered
12.8.5 Astex Pharmaceuticals Recent Development
12.9 Cyclacel Pharmaceuticals
12.9.1 Cyclacel Pharmaceuticals Corporation Information
12.9.2 Cyclacel Pharmaceuticals Business Overview
12.9.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Products Offered
12.9.5 Cyclacel Pharmaceuticals Recent Development
12.10 Daiichi Sankyo
12.10.1 Daiichi Sankyo Corporation Information
12.10.2 Daiichi Sankyo Business Overview
12.10.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Products Offered
12.10.5 Daiichi Sankyo Recent Development
12.11 Onconova Therapeutics
12.11.1 Onconova Therapeutics Corporation Information
12.11.2 Onconova Therapeutics Business Overview
12.11.3 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Products Offered
12.11.5 Onconova Therapeutics Recent Development
12.12 AstraZeneca
12.12.1 AstraZeneca Corporation Information
12.12.2 AstraZeneca Business Overview
12.12.3 AstraZeneca Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.12.4 AstraZeneca Non-Tyrosine Kinase Inhibitors Products Offered
12.12.5 AstraZeneca Recent Development
12.13 GlaxoSmithKline (GSK)
12.13.1 GlaxoSmithKline (GSK) Corporation Information
12.13.2 GlaxoSmithKline (GSK) Business Overview
12.13.3 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.13.4 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Products Offered
12.13.5 GlaxoSmithKline (GSK) Recent Development
12.14 Carna Biosciences
12.14.1 Carna Biosciences Corporation Information
12.14.2 Carna Biosciences Business Overview
12.14.3 Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Carna Biosciences Non-Tyrosine Kinase Inhibitors Products Offered
12.14.5 Carna Biosciences Recent Development
12.15 Celgene Corporation
12.15.1 Celgene Corporation Corporation Information
12.15.2 Celgene Corporation Business Overview
12.15.3 Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Celgene Corporation Non-Tyrosine Kinase Inhibitors Products Offered
12.15.5 Celgene Corporation Recent Development
12.16 Eternity Bioscience
12.16.1 Eternity Bioscience Corporation Information
12.16.2 Eternity Bioscience Business Overview
12.16.3 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.16.4 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Products Offered
12.16.5 Eternity Bioscience Recent Development
12.17 Jasco Pharmaceuticals
12.17.1 Jasco Pharmaceuticals Corporation Information
12.17.2 Jasco Pharmaceuticals Business Overview
12.17.3 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.17.4 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Products Offered
12.17.5 Jasco Pharmaceuticals Recent Development
13 Non-Tyrosine Kinase Inhibitors Manufacturing Cost Analysis
13.1 Non-Tyrosine Kinase Inhibitors Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Non-Tyrosine Kinase Inhibitors
13.4 Non-Tyrosine Kinase Inhibitors Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Non-Tyrosine Kinase Inhibitors Distributors List
14.3 Non-Tyrosine Kinase Inhibitors Customers
15 Market Dynamics
15.1 Non-Tyrosine Kinase Inhibitors Market Trends
15.2 Non-Tyrosine Kinase Inhibitors Opportunities and Drivers
15.3 Non-Tyrosine Kinase Inhibitors Market Challenges
15.4 Non-Tyrosine Kinase Inhibitors Market Restraints
15.5 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Non-Tyrosine Kinase Inhibitors Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Region (2015-2020)
Table 5. Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Region (2015-2020)
Table 6. Global Non-Tyrosine Kinase Inhibitors Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Non-Tyrosine Kinase Inhibitors Revenue Share by Region (2015-2020)
Table 8. Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Non-Tyrosine Kinase Inhibitors Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Non-Tyrosine Kinase Inhibitors Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Non-Tyrosine Kinase Inhibitors Revenue Share Forecast by Region (2021-2026)
Table 12. Global Non-Tyrosine Kinase Inhibitors (K Pcs) of Key Companies (2015-2020)
Table 13. Global Non-Tyrosine Kinase Inhibitors Sales Share by Company (2015-2020)
Table 14. Global Non-Tyrosine Kinase Inhibitors Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Non-Tyrosine Kinase Inhibitors Revenue Share by Company (2015-2020)
Table 16. Global Non-Tyrosine Kinase Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Tyrosine Kinase Inhibitors as of 2019)
Table 17. Global Non-Tyrosine Kinase Inhibitors Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Non-Tyrosine Kinase Inhibitors Manufacturing Sites and Area Served
Table 19. Manufacturers Non-Tyrosine Kinase Inhibitors Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Non-Tyrosine Kinase Inhibitors Players
Table 22. Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Type (2015-2020)
Table 23. Global Non-Tyrosine Kinase Inhibitors Sales Share by Type (2015-2020)
Table 24. Global Non-Tyrosine Kinase Inhibitors Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Non-Tyrosine Kinase Inhibitors Price (K Pcs) by Type (2015-2020)
Table 26. Global Non-Tyrosine Kinase Inhibitors Sales Share by Type (2021-2026)
Table 27. Global Non-Tyrosine Kinase Inhibitors Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Non-Tyrosine Kinase Inhibitors Revenue Share by Type (2021-2026)
Table 29. Global Non-Tyrosine Kinase Inhibitors Price (K Pcs) by Type (2021-2026)
Table 30. Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Application (2015-2020)
Table 31. Global Non-Tyrosine Kinase Inhibitors Sales Share by Application (2015-2020)
Table 32. Global Non-Tyrosine Kinase Inhibitors Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Non-Tyrosine Kinase Inhibitors Price (K Pcs) by Application (2015-2020)
Table 34. Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Application (2021-2026)
Table 35. Global Non-Tyrosine Kinase Inhibitors Sales Share by Application (2021-2026)
Table 36. Global Non-Tyrosine Kinase Inhibitors Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Non-Tyrosine Kinase Inhibitors Revenue Share by Application (2021-2026)
Table 38. Global Non-Tyrosine Kinase Inhibitors Price (K Pcs) by Application (2021-2026)
Table 39. United States Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Company (2015-2020)
Table 40. United States Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 41. United States Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Type (2015-2020)
Table 42. United States Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 43. United States Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Application (2015-2020)
Table 44. United States Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
Table 45. Europe Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 47. Europe Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 49. Europe Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 51. China Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Company (2015-2020)
Table 52. China Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 53. China Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Type (2015-2020)
Table 54. China Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 55. China Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Application (2015-2020)
Table 56. China Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
Table 57. Japan Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 59. Japan Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 61. Japan Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
Table 69. India Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Company (2015-2020)
Table 70. India Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 71. India Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Type (2015-2020)
Table 72. India Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 73. India Non-Tyrosine Kinase Inhibitors Sales (K Pcs) by Application (2015-2020)
Table 74. India Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2015-2020)
Table 75. Roche Corporation Information
Table 76. Roche Description and Business Overview
Table 77. Roche Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Roche Non-Tyrosine Kinase Inhibitors Product
Table 79. Roche Recent Development
Table 80. Eli Lilly Corporation Information
Table 81. Eli Lilly Description and Business Overview
Table 82. Eli Lilly Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Eli Lilly Non-Tyrosine Kinase Inhibitors Product
Table 84. Eli Lilly Recent Development
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. Novartis Non-Tyrosine Kinase Inhibitors Product
Table 89. Novartis Recent Development
Table 90. Array BioPharma Corporation Information
Table 91. Array BioPharma Description and Business Overview
Table 92. Array BioPharma Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Array BioPharma Non-Tyrosine Kinase Inhibitors Product
Table 94. Array BioPharma Recent Development
Table 95. Nerviano Medical Sciences Corporation Information
Table 96. Nerviano Medical Sciences Description and Business Overview
Table 97. Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product
Table 99. Nerviano Medical Sciences Recent Development
Table 100. Pfizer Corporation Information
Table 101. Pfizer Description and Business Overview
Table 102. Pfizer Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Pfizer Non-Tyrosine Kinase Inhibitors Product
Table 104. Pfizer Recent Development
Table 105. Merck KGaA Corporation Information
Table 106. Merck KGaA Description and Business Overview
Table 107. Merck KGaA Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Merck KGaA Non-Tyrosine Kinase Inhibitors Product
Table 109. Merck KGaA Recent Development
Table 110. Astex Pharmaceuticals Corporation Information
Table 111. Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Astex Pharmaceuticals Description and Business Overview
Table 113. Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product
Table 114. Astex Pharmaceuticals Recent Development
Table 115. Cyclacel Pharmaceuticals Corporation Information
Table 116. Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. Cyclacel Pharmaceuticals Description and Business Overview
Table 118. Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product
Table 119. Cyclacel Pharmaceuticals Recent Development
Table 120. Daiichi Sankyo Corporation Information
Table 121. Daiichi Sankyo Description and Business Overview
Table 122. Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product
Table 124. Daiichi Sankyo Recent Development
Table 125. Onconova Therapeutics Corporation Information
Table 126. Onconova Therapeutics Description and Business Overview
Table 127. Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product
Table 129. Onconova Therapeutics Recent Development
Table 130. AstraZeneca Corporation Information
Table 131. AstraZeneca Description and Business Overview
Table 132. AstraZeneca Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. AstraZeneca Non-Tyrosine Kinase Inhibitors Product
Table 134. AstraZeneca Recent Development
Table 135. GlaxoSmithKline (GSK) Corporation Information
Table 136. GlaxoSmithKline (GSK) Description and Business Overview
Table 137. GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 138. GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product
Table 139. GlaxoSmithKline (GSK) Recent Development
Table 140. Carna Biosciences Corporation Information
Table 141. Carna Biosciences Description and Business Overview
Table 142. Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 143. Carna Biosciences Non-Tyrosine Kinase Inhibitors Product
Table 144. Carna Biosciences Recent Development
Table 145. Celgene Corporation Corporation Information
Table 146. Celgene Corporation Description and Business Overview
Table 147. Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 148. Celgene Corporation Non-Tyrosine Kinase Inhibitors Product
Table 149. Celgene Corporation Recent Development
Table 150. Eternity Bioscience Corporation Information
Table 151. Eternity Bioscience Description and Business Overview
Table 152. Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 153. Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product
Table 154. Eternity Bioscience Recent Development
Table 155. Jasco Pharmaceuticals Corporation Information
Table 156. Jasco Pharmaceuticals Description and Business Overview
Table 157. Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 158. Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product
Table 159. Jasco Pharmaceuticals Recent Development
Table 160. Production Base and Market Concentration Rate of Raw Material
Table 161. Key Suppliers of Raw Materials
Table 162. Non-Tyrosine Kinase Inhibitors Distributors List
Table 163. Non-Tyrosine Kinase Inhibitors Customers List
Table 164. Non-Tyrosine Kinase Inhibitors Market Key Trends
Table 165. Non-Tyrosine Kinase Inhibitors Key Opportunities and Drivers
Table 166. Non-Tyrosine Kinase Inhibitors Market Challenges
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Non-Tyrosine Kinase Inhibitors Product Picture
Figure 2. Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Non-Tyrosine Kinase Inhibitors Market Share by Application in 2020 & 2026
Figure 6. Liver Cancer Examples
Figure 7. Respiratory Cancer Examples
Figure 8. Brain Cancer Examples
Figure 9. Others Examples
Figure 10. Global Non-Tyrosine Kinase Inhibitors Sales (K Pcs) Growth Rate (2015-2026)
Figure 11. Global Non-Tyrosine Kinase Inhibitors Revenue (US$ Million) Growth Rate (2015-2026)
Figure 12. Global Non-Tyrosine Kinase Inhibitors Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 13. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Region: 2015 VS 2020
Figure 14. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Region: 2021 VS 2026
Figure 15. United States Non-Tyrosine Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. United States Non-Tyrosine Kinase Inhibitors Sales (K Pcs) Growth Rate (2015-2026)
Figure 17. Europe Non-Tyrosine Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. Europe Non-Tyrosine Kinase Inhibitors Sales (Million USD) Growth Rate (2015-2026)
Figure 19. China Non-Tyrosine Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. China Non-Tyrosine Kinase Inhibitors Sales (Million USD) and Growth Rate (2015-2026)
Figure 21. Japan Non-Tyrosine Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Japan Non-Tyrosine Kinase Inhibitors Sales (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Non-Tyrosine Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia Non-Tyrosine Kinase Inhibitors Sales (Million USD) Growth Rate (2015-2026)
Figure 25. India Non-Tyrosine Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 26. India Non-Tyrosine Kinase Inhibitors Sales (Million USD) Growth Rate (2015-2026)
Figure 27. Global 5 Largest Non-Tyrosine Kinase Inhibitors Players Market Share by Revenue in Non-Tyrosine Kinase Inhibitors 2015 & 2019
Figure 28. Non-Tyrosine Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 29. Global Non-Tyrosine Kinase Inhibitors Revenue Share by Type (2015-2020)
Figure 30. Global Non-Tyrosine Kinase Inhibitors Revenue Growth Rate by Type in 2015 & 2019
Figure 31. Global Non-Tyrosine Kinase Inhibitors Revenue Share by Application (2015-2020)
Figure 32. Global Non-Tyrosine Kinase Inhibitors Revenue Growth Rate by Application in 2015 & 2019
Figure 33. United States Non-Tyrosine Kinase Inhibitors Sales Market Share by Type in 2019
Figure 34. United States Non-Tyrosine Kinase Inhibitors Sales Market Share by Type in 2019
Figure 35. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share by Company in 2019
Figure 36. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share by Type in 2019
Figure 37. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share by Application in 2019
Figure 38. China Non-Tyrosine Kinase Inhibitors Sales Market Share by Company in 2019
Figure 39. China Non-Tyrosine Kinase Inhibitors Sales Market Share by Type in 2019
Figure 40. China Non-Tyrosine Kinase Inhibitors Sales Market Share by Application in 2019
Figure 41. Japan Non-Tyrosine Kinase Inhibitors Sales Market Share by Company in 2019
Figure 42. Japan Non-Tyrosine Kinase Inhibitors Sales Market Share by Type in 2019
Figure 43. Japan Non-Tyrosine Kinase Inhibitors Sales Market Share by Application in 2019
Figure 44. Southeast Asia Non-Tyrosine Kinase Inhibitors Sales Market Share by Company in 2019
Figure 45. Southeast Asia Non-Tyrosine Kinase Inhibitors Sales Market Share by Type in 2019
Figure 46. Southeast Asia Non-Tyrosine Kinase Inhibitors Sales Market Share by Application in 2019
Figure 47. India Non-Tyrosine Kinase Inhibitors Sales Market Share by Company in 2019
Figure 48. India Non-Tyrosine Kinase Inhibitors Sales Market Share by Type in 2019
Figure 49. India Non-Tyrosine Kinase Inhibitors Sales Market Share by Application in 2019
Figure 50. Key Raw Materials Price Trend
Figure 51. Manufacturing Cost Structure of Non-Tyrosine Kinase Inhibitors
Figure 52. Manufacturing Process Analysis of Non-Tyrosine Kinase Inhibitors
Figure 53. Non-Tyrosine Kinase Inhibitors Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Porter's Five Forces Analysis
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
がんCDK阻害剤の世界市場レポート2020 Market Analysis and Insights: Global Cancer CDK Inhibitors Market The global Cancer CDK Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Cancer CDK Inhibitors Scope and Market Size The global Cancer CDK Inhibi…- プロテインキナーゼ阻害剤の世界市場レポート2020 Market Analysis and Insights: Global Protein Kinase Inhibitor Market The global Protein Kinase Inhibitor market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Protein Kinase Inhibitor Scope and Market Size The global Protein …
- レニン阻害剤の世界市場レポート2020 Renin inhibitors are one of four classes of compounds that affect the renin-angiotensin-aldosterone system. Renin inhibitors produce vasodilation by inhibiting the activity of renin, which is responsible for stimulating angiotensin II formation. Renin is a proteolytic enzyme that is released by the …
- ヒストンデアセチラーゼ阻害剤の世界市場レポート2020 Market Analysis and Insights: Global Histone Deacetylase Inhibitors Market The global Histone Deacetylase Inhibitors market size is projected to reach US$ 2043.7 million by 2026, from US$ 1028 million in 2020, at a CAGR of 12.1% during 2021-2026. Global Histone Deacetylase Inhibitors Scope and Marke…
- がんヤヌスキナーゼ阻害剤の世界市場レポート2020 The pan-JAK inhibitor tofacitinib improves the delivery of therapeutic antibodies in cancer. Monoclonal antibodies and antibody-drug conjugates (ADCs) directed against tumor antigens are increasingly used for therapy in a variety of cancers. Market Analysis and Insights: Global Cancer Janus Kinase I…